



## Appendix 4D

### Half-year report

Name of entity

**INTEGRATED RESEARCH LIMITED**

ABN

76 003 588 449

Reporting period  
(half-year ended)

31 December 2022

Previous corresponding  
period (half-year ended)

31 December 2021

#### For announcement to the market

*Extracts from this report for announcement to the market*

					A\$000
Revenues from ordinary activities	Up	19%	to		38,435
Profit before tax attributable to members	Up	405%	to		3,204
Net profit for the period attributable to members	Up	80%	to		3,217

	Amount per security	Franked amount per security
<b>Dividends (distributions)</b>		
Interim dividend	Nil	N/A
Previous corresponding period	Nil	N/A

#### Brief explanation of results

Please refer to page 2 'Review of Operations' for an explanation of the results.  
This information should be read in conjunction with Integrated Research Limited 2022 Annual Report.

The information provided in this report contains all the information required by ASX Listing Rule 4.2A.

	<b>December 2022</b> <b>Cents</b>	December 2021 Cents
<b>NTA backing</b>		
Net tangible asset backing per ordinary security	34.93	32.48

	<b>December 2022</b> <b>\$'000</b>	December 2021 \$'000
<b>Dividends</b>		
No interim dividend has been declared for the current period	Nil	Nil
Total dividends provided for or paid	Nil	Nil



**INTEGRATED RESEARCH LIMITED AND CONTROLLED  
ENTITIES**

FOR THE HALF-YEAR ENDED  
31 DECEMBER 2022

ABN: 76 003 588 449

ASX CODE: IRI

**Contents**

<b>Directors' Report</b>	<b>1</b>
<b>Consolidated Interim Financial Report</b>	
Consolidated Statement of Comprehensive Income	4
Consolidated Statement of Financial Position	5
Consolidated Statement of Changes in Equity	6
Consolidated Statement of Cash Flows	7
Notes to the Consolidated Financial Statements	8
Directors' Declaration	13
Auditor's Independence Declaration	14
Independent Auditor's Review Report	15

## Directors' Report

The Directors present their report together with the consolidated financial report for the half-year ended 31 December 2022 and the review report thereon.

### Directors

The Directors of Integrated Research Limited at any time during or since the end of the half-year are:

Peter Lloyd – Independent Non-Executive Director and Chairman

John Ruthven – Managing Director and Chief Executive Officer

Cathy Aston – Independent Non-Executive Director

Allan Brackin – Independent Non-Executive Director

Anne Myers – Independent Non-Executive Director

James Scott – Independent Non-Executive Director

### Principal Activities

Integrated Research Limited's principal activities are the design, development, implementation and sale of systems and applications management computer software for business-critical computing, Unified Communication networks and Payment networks.

### Half-Year Results

The following table summarises the key revenue, expense and profit results for the consolidated entity for the half-year ended 31 December 2022 compared to the previous corresponding period:

In thousands of AUD	2022	2021	Change %
Revenue from licence fees	26,374	17,992	47%
Revenue from maintenance fees	7,450	7,828	(5%)
Revenue from subscription fees	855	518	65%
Revenue from testing solution services	1,856	2,249	(17%)
Revenue from professional services	1,900	3,700	(49%)
<b>Total revenue</b>	<b>38,435</b>	<b>32,287</b>	<b>19%</b>
<b>Total expenses</b>	<b>(36,251)</b>	<b>(34,658)</b>	<b>5%</b>
<b>Profit/(loss) before finance income, other losses, and income tax</b>	<b>2,184</b>	<b>(2,371)</b>	<b>(192%)</b>
Other (losses) /gains	(17)	2,208	(101%)
Finance income	1,037	798	30%
<b>Profit before tax</b>	<b>3,204</b>	<b>635</b>	<b>405%</b>
Income tax benefit <sup>1</sup>	13	1,153	(99%)
<b>Net profit after income tax</b>	<b>3,217</b>	<b>1,788</b>	<b>80%</b>

The Company reported profit after tax of \$3.2 million and revenue of \$38.4 million for the half year ended 31 December 2022. The result represents a 80% increase on the prior equivalent half. Strong revenue results from Asia Pacific (up 49%), Europe (up 11%) and the Americas (up 10%). Total Contract Value<sup>2</sup> ("TCV") of \$38.9 million was up 22% on the previous corresponding period noting that the first half was a strong period for renewal business. Of the TCV written in the current half, 24% was attributable to either new customers or new products sold to existing customers. There were 17 new customers added during the period. The Company's transact and infrastructure business have gathered momentum, growing 164% and 81% respectively period on period.

<sup>1</sup> The effective income tax benefit rate is not 30% of pre-tax profit due to permanent differences including estimates for the R&D tax incentives.

<sup>2</sup> Total contract value means the total value of a revenue generating contract written in the period of performance less any residual value from a previous related contract. The value includes software licence and related maintenance, cloud, testing and consulting services.

## Directors' Report (continued)

### Review of Operations

#### Revenue

Revenue for the reporting period was \$38.4 million, an increase of 19% over the previous corresponding period. The following table presents Company revenue for each of the relevant product groups:

In thousands of AUD	2022	2021	Change %
Collaborate	20,414	19,677	4%
Infrastructure	8,523	5,199	64%
Transact	7,598	3,711	105%
Professional Services	1,900	3,700	(49%)
<b>Total revenue</b>	<b>38,435</b>	<b>32,287</b>	<b>19%</b>

The following table presents revenue in native currency by geographic segment:

	2022	2021	Change %
Americas (USD'000)	13,553	13,528	0%
Europe (£'000)	3,996	3,439	16%
Asia Pacific (A\$'000)	11,002	7,389	49%

#### Expenses

The Company's operating cost base increased by 5% to \$36.3 million. The increase in operating expenses was driven by an increase of staff related costs.

The following table represents an analysis of research and development:

In thousands of AUD	2022	2021
Gross research and development spending	11,177	11,074
Capitalisation of development expenses	(4,483)	(5,862)
Amortisation of capitalised expenses	5,265	5,664
<b>Net research and development expenses</b>	<b>11,959</b>	<b>10,876</b>

#### Cashflow

Cash receipts from customers was \$31.7 million for the reporting period with no debtor factoring. Cash receipts were lower than the corresponding period due to lower TCV in prior financial periods.

For the financial year ended 30 June 2022, as detailed in the Directors' Report for that financial year, no dividends were paid to the holders of fully paid ordinary shares.

#### Statement of Financial Position

At 31 December 2022, the Company held \$9.3 million in cash (30 June 2022: \$12.3 million). Receivables were higher at the end of the period due to strong TCV towards the end of the period.

**Directors' Report (continued)**

**Interim Dividend**

The Board did not declare an interim dividend. The assessment of future dividends will be made after the annual results are available.

**Lead Auditor's Independence Declaration under Section 307C of the Corporations Act 2001**

The lead auditor's independence declaration is set out on page 14 and forms part of the Directors' Report for the half-year ended 31 December 2022.

**Rounding off**

Integrated Research Limited is of a kind referred to in ASIC Legislative instrument 2016/191 and in accordance with the Class Order, amounts in the financial report and Directors' Report have been rounded off to the nearest thousand dollars, unless otherwise stated.

Signed in accordance with a resolution of the Directors:



Peter Lloyd  
Chairman



John Ruthven  
Managing Director and Chief Executive Officer

Dated at North Sydney this 16<sup>th</sup> day of February 2023.

**Consolidated Statement of Comprehensive Income**

For the half-year ended 31 December 2022

In thousands of AUD

	Note	December 2022	December 2021
<b>Continuing Operations</b>			
<i>Revenue from contracts with customers</i>			
Licence fees		26,374	17,992
Maintenance fees		7,450	7,828
Subscription fees		855	518
Testing solution services		1,856	2,249
Professional services		1,900	3,700
<b>Total revenue</b>	3	<b>38,435</b>	<b>32,287</b>
<i>Expenditure:</i>			
Research and development		(11,959)	(10,876)
Sales, professional services and marketing expenses		(20,215)	(20,867)
General and administration expenses		(4,077)	(2,915)
<b>Total expenditure</b>		<b>(36,251)</b>	<b>(34,658)</b>
Other (losses) and gains		(17)	2,208
<b>Profit/(loss) before finance income and tax</b>		<b>2,167</b>	<b>(163)</b>
Finance income		1,037	798
<b>Profit before tax</b>		<b>3,204</b>	<b>635</b>
Income tax benefit		13	1,153
<b>Profit for the period</b>		<b>3,217</b>	<b>1,788</b>
<b>Other comprehensive income</b>			
<b>Items that may be reclassified subsequently to profit</b>			
Foreign exchange translation differences		359	625
<b>Other comprehensive income for the period</b>		<b>359</b>	<b>625</b>
<b>Total comprehensive income for the period</b>		<b>3,576</b>	<b>2,413</b>
<i>Profit attributable to:</i>			
Members of Integrated Research		3,217	1,788
<i>Total comprehensive income attributable to:</i>			
Members of Integrated Research		3,576	2,413
Earnings per share attributable to members of Integrated Research			
Basic earnings per share to ordinary equity holders (AUD cents)	4	1.86	1.04
Diluted earnings per share to ordinary equity holders (AUD cents)	4	1.86	1.03

The consolidated statement of comprehensive income is to be read in conjunction with the accompanying notes set out on pages 8 to 12.

**Consolidated Statement of Financial Position**

As at 31 December 2022

In thousands of AUD

	December 2022	June 2022
<b>Current assets</b>		
Cash and cash equivalents	9,256	12,329
Trade and other receivables	50,758	46,812
Current tax assets	211	564
Other current assets	3,380	3,657
Total current assets	63,605	63,362
<b>Non-current assets</b>		
Trade and other receivables	23,981	21,995
Other financial assets	202	244
Property, plant and equipment	569	744
Right-of-use assets	3,706	4,407
Deferred tax assets	2,390	1,333
Intangible assets	30,571	31,309
Other non-current assets	1,125	1,050
Total non-current assets	62,544	61,082
<b>Total assets</b>	126,149	124,444
<b>Current liabilities</b>		
Trade and other payables	9,925	10,131
Provisions	3,514	3,650
Income tax liabilities	701	-
Deferred revenue	13,877	14,121
Lease liabilities	1,726	1,710
Other financial liabilities	107	654
Total current liabilities	29,850	30,266
<b>Non-current liabilities</b>		
Deferred tax liabilities	1,655	2,487
Provisions	861	905
Deferred revenue	360	504
Lease liabilities	2,439	3,161
Other financial liabilities	2	8
Total non-current liabilities	5,317	7,065
<b>Total liabilities</b>	35,167	37,331
<b>Net assets</b>	90,982	87,113
<b>Equity</b>		
Issued capital	1,667	1,667
Reserves	7,289	6,637
Retained earnings	82,026	78,809
<b>Total equity attributable to members of Integrated Research</b>	90,982	87,113

The consolidated statement of financial position is to be read in conjunction with the accompanying notes set out on pages 8 to 12.



**Consolidated Statement of Changes in Equity**

For the half-year ended 31 December 2022

In thousands of AUD

	Share Capital	Translation Reserve	Employee Benefits Reserve	Retained Earnings	Total
<b>Balance as at 1 July 2022</b>	<b>1,667</b>	<b>641</b>	<b>5,996</b>	<b>78,809</b>	<b>87,113</b>
Profit for the period	-	-	-	3,217	3,217
Other comprehensive income	-	359	-	-	359
Total comprehensive income for the period	-	359	-	3,217	3,576
Expensed employee options and performance rights	-	-	293	-	293
Payment of dividends	-	-	-	-	-
<b>Balance at 31 December 2022</b>	<b>1,667</b>	<b>1,000</b>	<b>6,289</b>	<b>82,026</b>	<b>90,982</b>

	Share Capital	Translation Reserve	Employee Benefits Reserve	Retained Earnings	Total
<b>Balance as at 1 July 2021</b>	<b>1,667</b>	<b>(666)</b>	<b>5,077</b>	<b>77,264</b>	<b>83,342</b>
Profit for the period	-	-	-	1,788	1,788
Other comprehensive income	-	625	-	-	625
Total comprehensive income for the period	-	625	-	1,788	2,413
Expensed employee options and performance rights	-	-	532	-	532
Payment of dividends	-	-	-	-	-
<b>Balance at 31 December 2021</b>	<b>1,667</b>	<b>(41)</b>	<b>5,609</b>	<b>79,052</b>	<b>86,287</b>

*The consolidated statement of changes in equity is to be read in conjunction with the accompanying notes set out on pages 8 to 12.*

**Consolidated Statement of Cash Flows**  
For the half-year ended 31 December 2022  
In thousands of AUD

	December 2022	December 2021
<b>Cash flows from operating activities</b>		
Cash receipts from customers	31,724	37,723
Cash paid to suppliers and employees	(29,907)	(28,607)
Cash generated from operations	1,817	9,116
Income taxes paid	(812)	(463)
<b>Net cash from operating activities</b>	<b>1,005</b>	<b>8,653</b>
<b>Cash flows from investing activities</b>		
Payments for capitalised development	(4,483)	(5,862)
Payments for property, plant and equipment	(198)	(60)
Interest received	1,117	940
<b>Net cash used in investing activities</b>	<b>(3,564)</b>	<b>(4,982)</b>
<b>Cash flows from financing activities</b>		
Payment of lease liabilities	(705)	(902)
Interest payments	(81)	(142)
Payment of dividend	-	-
<b>Net cash used in financing activities</b>	<b>(786)</b>	<b>(1,044)</b>
<b>Net increase/(decrease) in cash and cash equivalents</b>	<b>(3,345)</b>	<b>2,627</b>
Cash and cash equivalents at 1 July	12,329	12,149
Effects of exchange rate changes on cash	272	155
<b>Cash and cash equivalents at 31 December</b>	<b>9,256</b>	<b>14,931</b>

*The consolidated statement of cash flows is to be read in conjunction with the accompanying notes set out on pages 8 to 12.*

**Notes to the Consolidated Financial Statements**

For the half-year ended 31 December 2022

In thousands of AUD

**Note 1. Significant accounting policies**

**a) Statement of Compliance**

The half-year financial report is a general purpose financial report prepared in accordance with the Corporations Act 2001 and AASB 134 Interim Financial Reporting. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 Interim Financial Reporting. The half-year report does not include notes of the type normally included in an annual financial report and should be read in conjunction with the most recent annual financial report.

**b) Basis of Preparation**

The interim financial report is prepared on the historical cost convention, with the exception of financial instruments for the purposes of cash flow hedges, which are at fair value. All amounts are presented in Australian dollars unless otherwise stated.

Integrated Research Limited is a for-profit Company limited by ordinary shares.

Integrated Research Limited is of a kind referred to in ASIC Legislative instrument 2016/191. In accordance with that Class Order, amounts in the financial report and Directors' Report and the half-year financial report have been rounded off to the nearest thousand dollars, unless otherwise indicated.

**New accounting standards and interpretations**

The accounting policies and methods of computation adopted in the preparation of the half-year financial report are consistent with those adopted and disclosed in Integrated Research Limited's 2022 annual financial report. These accounting policies are consistent with Australian Accounting Standards and with International Financial Reporting Standards.

**Note 2. Segment information**

The Chief Operating Decision Maker, “CODM”, (being the Chief Executive Officer) reviews a variety of information on the performance of Prognosis across the group for the purpose of resource allocation.

The principal geographical regions are The Americas – Operating from the United States with responsibility for the countries in North, Central and South America, Europe – operating from the United Kingdom and Germany with responsibility for the countries in Europe, Asia Pacific – operating from Australia and Singapore with responsibility for the countries in the rest of the world and Corporate Australia – with responsibility for research and development and corporate head office functions of the Company. Inter-segment pricing is determined on an arm’s length basis.

Information regarding these geographic regions is presented below.

	Americas		Europe		Asia Pacific		Corporate Australia <sup>1</sup>		Eliminations		Consolidated	
In thousands of AUD	2022	2021	2022	2021	2022	2021	2022	2021	2022	2021	2022	2021
Sales to customers outside the consolidated entity	20,310	18,504	7,122	6,394	11,002	7,389	-	-	-	-	38,435	32,287
Inter-region revenue	-	-	-	-	-	-	18,687	12,553	(18,687)	(12,553)	-	-
Total regional revenue	20,310	18,504	7,122	6,394	11,002	7,389	18,687	12,553	(18,687)	(12,553)	38,435	32,287

	Americas (USD)		Europe (UK Sterling)	
In local currency <sup>2</sup>	2022	2021	2022	2021
Sales to customers outside the consolidated entity	13,553	13,528	3,996	3,439
Inter-region revenue	-	-	-	-
Total regional revenue	13,553	13,528	3,996	3,439

<sup>1</sup> Corporate Australia includes research and development, hedging and corporate head office functions of Integrated Research Limited.

<sup>2</sup> Segment results represented in local currencies.

**Note 3. Revenue from contracts with customers**

Information regarding the disaggregation of the Company’s revenues from contracts with customers is presented below.

	Consolidated December 2022	Consolidated December 2021
In thousands of AUD		
Timing of revenue recognition		
At a point in time	26,374	17,992
Over time	12,061	14,295
Total Revenue from contracts with customers	38,435	32,287
Type of product group		
Collaborate	20,414	19,677
Infrastructure	8,523	5,199
Transact	7,598	3,711
Professional Services	1,900	3,700
Total revenue	38,435	32,287

#### Note 4. Earnings per Share

##### *Basic earnings per share*

The calculation of basic earnings per share for the half-year ended 31 December 2022 was based on the profit attributable to ordinary shareholders of \$3,217,000 (half-year ended 31 December 2021: \$1,788,000) and a weighted average number of ordinary shares outstanding during the half-year ended 31 December 2022 of 172,775,305 (half-year ended 31 December 2021 of 172,334,138).

##### *Diluted earnings per share*

The calculation of diluted earnings per share for the half-year ended 31 December 2022 was based on the profit attributable to ordinary shareholders of \$3,217,000 (half-year ended 31 December 2021: \$1,788,000) and a weighted average number of ordinary shares (diluted) outstanding during the half-year ended 31 December 2022 of 172,799,939 (half-year ended 31 December 2021: 172,852,323).

#### Note 5. Employee Equity benefits

##### *Performance Rights and Options Plan – November 2011*

The consolidated entity has a performance rights and options plan that enables Integrated Research Limited to offer performance rights and options to eligible employees to obtain shares in Integrated Research Limited contingent upon performance conditions being met. The performance conditions may be a service period only or a service period and either a net profit after tax or total shareholder return hurdle. The performance rights are automatically exercised into shares upon the performance conditions being met at zero cost. Options are exercisable by employees after the vesting date but before the expiry date (which is five years from the grant date) at their exercise price. The following instruments were granted during the period:

Grant Date	Type	Quantity	Exercise price	Expiry date
September 2022	Performance rights	238,095	-	September 2025
November 2022	Performance rights	1,319,218	-	August 2025
December 2022	Performance rights	850,000	-	August 2025
December 2022	Performance rights	4,758,750	-	September 2025

The following instruments were outstanding as at 31 December 2022:

Grant Date	Type	Quantity	Exercise price	Expiry date
September 2020	Performance rights	13,002	-	August 2023
November 2020	Performance rights	112,792	-	August 2023
August 2021	Options	1,147,332	\$1.98	August 2026
November 2021	Performance rights	475,206	-	August 2024
March 2022	Performance rights	13,468	-	August 2024
May 2022	Performance rights	68,686	-	August 2024
September 2022	Performance rights	238,095	-	September 2025
November 2022	Performance rights	135,600	-	August 2025
November 2022 <sup>1</sup>	Performance rights	2,033,618	-	August 2025
December 2022	Performance rights	4,758,750	-	September 2025

<sup>1</sup> Performance rights allocated have market hurdles attached to their vesting conditions to be tested in August 2023, August 2024 and August 2025.

During the period, the following performance rights were exercised into ordinary shares for nil consideration.

Grant Date	Number of Rights	Expiry date
August 2019	40,000	August 2022
September 2019	37,618	August 2022
November 2019	79,593	August 2022
September 2020	6,503	August 2022
November 2021	305,766	September 2022

**Note 6. Financial Instruments**

**Forward foreign exchange contracts**

The consolidated entity is exposed to foreign currency risk on sales and purchases that are denominated in a currency other than the AUD. The currencies giving rise to this risk are primarily United States Dollar, UK Sterling and the Euro.

The consolidated entity uses option and forward exchange contracts to hedge its foreign currency risk. The option and forward exchange contracts have maturities of less than two years after the reporting date.

The consolidated entity classifies its option and forward exchange contracts hedging forecasted transactions as cash flow hedges and measures them at fair value. The following table details the option and forward foreign currency contracts outstanding as at reporting date:

Outstanding contracts	Average Exchange Rate		Foreign Currency		Contract Value		Fair Value	
	2022	2021	2022 FC'000	2021 FC'000	2022 A\$'000	2021 A\$'000	2022 A\$'000	2021 A\$'000
<b>FX Forwards</b>								
<u>Sell US Dollar</u>								
Less than 3 months	0.71	0.75	750	3,700	1,058	4,949	(48)	(148)
3 to 6 months	0.72	0.76	750	2,500	1,043	3,307	(59)	(135)
6 to 9 months	-	0.76	-	1,500	-	1,962	-	(103)
9 to 12 months	-	0.74	-	1,000	-	1,344	-	(32)
12 to 15 months	-	0.73	-	500	-	699	-	9
<u>Sell Euros</u>								
3 to 6 months	-	0.62	-	200	-	321	-	8
<u>Sell Sterling</u>								
3 to 6 months	-	0.53	-	400	-	750	-	5
<b>FX Options</b>								
<u>Put US Dollar</u>								
6 to 9 months	-	0.67	-	2,000	-	3,008	-	(23)
9 to 12 months	-	0.70	-	1,000	-	1,429	-	(31)
<u>Call US Dollar</u>								
6 to 9 months	-	0.75	-	2,000	-	2,685	-	49
9 to 12 months	-	0.75	-	1,000	-	1,335	-	32
							(107)	(369)

These hedge assets and liabilities are classified as a level 2 fair value measurement, being derived from inputs provided from financial institutes, rather than quoted prices that are observable for the asset either directly (i.e. as prices) or indirectly (i.e. derived from prices). The fair value measurement of the over-the-counter forward contract would not qualify as Level 1 as there is not a quoted price for the actual contract, even though data used to value the contract may be derived entirely from active foreign-exchange and interest-rate market.

**Fair value of financial instruments**

The carrying value of financial assets and financial liabilities of the consolidated entity is a reasonable approximation of their fair value.

Financial assets

For non-current trade debtors Integrated Research Limited has considered a discount rate to recognise the net present value of the debtors. Level 3 inputs have been considered including corporate borrowing rates, size of the customer and jurisdiction of the customer. A discounted cashflow model was used to derive the fair value. The range of discount rates was between 3.5% to 7.5%.

**Note 6. Financial Instruments (continued)**

**Credit risk management**

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in financial loss to the consolidated entity. The consolidated entity has adopted a policy of only dealing with creditworthy counterparties and obtaining sufficient collateral where appropriate, as a means of mitigating the risk of financial loss from defaults.

Trade receivables consist of a large number of customers, spread across diverse industries and geographical areas. The largest single counterparty balance with any one customer at 31 December 2022 was \$5.7 million (June 2022: \$6.0 million). Ongoing credit evaluation is performed on the financial condition of accounts.

The Company has a program to sell selected account receivable balances to a third party without recourse. There were no sales of accounts receivables during the current or prior comparative reporting period. The Company continues to bear maintenance support obligations to the end customers which are carried as a liability in the deferred revenue account of the Company's balance sheet of \$0.7 million (June 2022: \$0.9 million).

The credit risk on liquid funds and derivative financial instruments is limited because the counterparties are banks with high credit ratings assigned by international credit-rating agencies.

**Note 7. Contingent liabilities**

IR is in commercial dispute with a client, with a claim for loss and damage. IR strongly refutes the claim, and will continue to defend the matter.

**Note 8. Subsequent events**

There were no events after the interim balance sheet date which are expected to have a material effect on the consolidated entity's financial position.

**Directors' Declaration**

In accordance with a resolution of the directors of Integrated Research Limited:

In the opinion of the directors:

- a) The financial statements and notes of Integrated Research Limited for the half-year ended 31 December 2022 are in accordance with the Corporations Act 2001, including:
  - (i) Giving a true and fair view of the consolidated entity's financial position as at 31 December 2022 and of its performance for the half-year ended on that date; and
  - (ii) Complying with Accounting Standards and the Corporations Regulations 2001.
- b) There are reasonable grounds to believe that Integrated Research Limited will be able to pay its debts as and when they become due and payable.

Dated at North Sydney this 16<sup>th</sup> day of February 2023.

On behalf of the Directors



Peter Lloyd  
Chairman



John Ruthven  
Managing Director and Chief Executive Officer





**Building a better  
working world**

Ernst & Young  
200 George Street  
Sydney NSW 2000 Australia  
GPO Box 2646 Sydney NSW 2001

Tel: +61 2 9248 5555  
Fax: +61 2 9248 5959  
ey.com/au

## **Auditor's Independence Declaration to the Directors of Integrated Research Limited**

As lead auditor for the review of Integrated Research Limited for the half-year ended 31 December 2022, I declare to the best of my knowledge and belief, there have been:

- a) No contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review;
- b) No contraventions of any applicable code of professional conduct in relation to the review; and
- c) No non-audit services provided that contravene any applicable code of professional conduct in relation to the review.

This declaration is in respect of Integrated Research Limited and the entities it controlled during the financial period.

Ernst & Young

Julian M. O'Brien  
Partner  
16 February 2023

## Independent Auditor's Review Report to the Members of Integrated Research Limited

### Report on the Half-Year Financial Report

#### Conclusion

We have reviewed the accompanying half-year financial report of Integrated Research Limited (the Company) and its subsidiaries (collectively the Group), which comprises the consolidated statement of financial position as at 31 December 2022, the consolidated statement of comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the half-year ended on that date, notes comprising a summary of significant accounting policies and other explanatory information, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of the Group does not comply with the *Corporations Act 2001*, including:

- a. Giving a true and fair view of the consolidated financial position of the Group as at 31 December 2022 and of its consolidated financial performance for the half-year ended on that date; and
- b. Complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

#### Basis for conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity* (ASRE 2410). Our responsibilities are further described in the *Auditor's responsibilities for the review of the half-year financial report* section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

#### Directors' Responsibilities for the Half-Year Financial Report

The directors of the Company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.


#### Auditor's Responsibility

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 31 December 2022 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

**Independence**

In conducting our review, we have complied with the independence requirements of the Corporations Act 2001.



Ernst & Young



Julian M. O'Brien  
Partner  
Sydney  
16 February 2023